Health-related quality-of-life assessment in CLEOPATRA, a phase III study combining pertuzumab with trastuzumab and docetaxel in metastatic breast cancer.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Annals of Oncology

• Publication date

  2013-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/annonc/mdt274PMID 23868905
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Exploration of oncologists’ attitudes toward and perceived value of patient-reported outcomes

  2013cited by this paper
• Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study.

  2013influential reference
• Informal caregiving to older cancer patients: preliminary research outcomes and implications.

  2013cited by this paper
• Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.

  2012influential reference
• Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial.

  2012cited by this paper
• Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer.

  2012cited by this paper
• Adverse events with pertuzumab and trastuzumab: Evolution during treatment with and without docetaxel in CLEOPATRA.

  2012influential reference
• Pathological complete response rates after neoadjuvant chemoradiation (CRT) for rectal cancer: Do novel agents have a role?

  2012cited by this paper
• Phase II trial of galiximab ( anti-CD 80 monoclonal antibody ) plus rituximab ( CALGB 50402 ) : Follicular Lymphoma International Prognostic Index ( FLIPI ) score is predictive of upfront immunotherapy responsiveness

  2012cited by this paper
• Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.

  2012cited by this paper
• Retrospective study of the effect of disease progression on patient reported outcomes in HER-2 negative metastatic breast cancer patients

  2011cited by this paper
• Quality-of-life measurement in randomized clinical trials in breast cancer: an updated systematic review (2001-2009).

  2011cited by this paper
• Impact of lapatinib plus trastuzumab versus single-agent lapatinib on quality of life of patients with trastuzumab-refractory HER2+ metastatic breast cancer.

  2011cited by this paper
• Quality-of-life and quality-adjusted survival (Q-TWiST) in patients receiving lapatinib in combination with paclitaxel as first-line treatment for metastatic breast cancer

  2010cited by this paper
• Effect of trastuzumab on health-related quality of life in patients with HER2-positive metastatic breast cancer: data from three clinical trials.

  2010cited by this paper
• Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer.

  2010cited by this paper
• Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy.

  2010cited by this paper
• Lapatinib plus capecitabine versus capecitabine alone for HER2+ (ErbB2+) metastatic breast cancer: quality-of-life assessment

  2009cited by this paper
• Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.

  2005cited by this paper
• Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.

  2005cited by this paper
• Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

  2005cited by this paper
• The HER-2-Targeting Antibodies Trastuzumab and Pertuzumab Synergistically Inhibit the Survival of Breast Cancer Cells

  2004cited by this paper
• A combination of distribution- and anchor-based approaches determined minimally important differences (MIDs) for four endpoints in a breast cancer scale.

  2004cited by this paper
• Oncologists' use of quality of life information: Results of a survey of Eastern Cooperative Oncology Group physicians

  2004cited by this paper
• Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex.

  2004cited by this paper
• Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193).

  2003cited by this paper
• Health-related quality-of-life measurement in randomized clinical trials in breast cancer--taking stock.

  2003cited by this paper
• Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth.

  2002cited by this paper
• Effects on quality of life of combined trastuzumab and chemotherapy in women with metastatic breast cancer.

  2002influential reference
• Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

  2001cited by this paper
• Reliability and validity of the Functional Assessment of Cancer Therapy-Breast quality-of-life instrument.

  1997cited by this paper

• Molecular heterogeneity and MYC dysregulation in triple-negative breast cancer: genomic advances and therapeutic implications

  2025cites this paper
• Real-world Outcomes of Dual HER2 Blockade Therapy in Metastatic HER2-Positive Breast Cancer: from Induction to Maintenance

  2024cites this paper
• The Cost-Effectiveness of Pertuzumab for the Treatment of Metastatic HER2+ Breast Cancer in Czechia: A Semi-Markov Model Using Cost States.

  2023cites this paper
• HER2-Directed Therapy in Advanced Breast Cancer: Benefits and Risks

  2023cites this paper
• Effectiveness of Adjuvant Pembrolizumab vs High-Dose Interferon or Ipilimumab for Quality-of-Life Outcomes in Patients With Resected Melanoma: A Secondary Analysis of the SWOG S1404 Randomized Clinical Trial.

  2022cites this paper
• Pertuzumab retreatment for HER2‐positive advanced breast cancer: A randomized, open‐label phase III study (PRECIOUS)

  2022cites this paper
• Patient-reported outcomes predict survival and adverse events following anticancer treatment initiation in advanced HER2-positive breast cancer

  2022cites this paper
• Health-related quality of life in older patients with HER2+ metastatic breast cancer: Comparing pertuzumab plus trastuzumab with or without metronomic chemotherapy in a randomised open-label phase II clinical trial.

  2022cites this paper
• Prioritising systemic cancer therapies applying ESMO’s tools and other resources to assist in improving cancer care globally: the Kazakh experience

  2022cites this paper
• Mediation of Tumor Cell Death by Naked Antibodies

  2021cites this paper
• Neratinib + capecitabine sustains health-related quality of life in patients with HER2-positive metastatic breast cancer and ≥ 2 prior HER2-directed regimens

  2021cites this paper
• Patient-reported function, health-related quality of life, and symptoms in APHINITY: pertuzumab plus trastuzumab and chemotherapy in HER2-positive early breast cancer

  2021cites this paper
• The role of chemotherapy in treatment of advanced breast cancer: an overview for clinical practice.

  2020cites this paper
• Correction to: Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (

  2020cites this paper
• Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERA

  2020cites this paper
• Targeting HER2 in Breast Cancer: Latest Developments on Treatment Sequencing and the Introduction of Biosimilars

  2020cites this paper
• The efficacy and safety of pertuzumab plus trastuzumab and docetaxel as a first-line therapy in Japanese patients with inoperable or recurrent HER2-positive breast cancer: the COMACHI study

  2020cites this paper
• Implementation of an Electronic Patient-Reported Outcome App for Health-Related Quality of Life in Breast Cancer Patients: Evaluation and Acceptability Analysis in a Two-Center Prospective Trial

  2019cites this paper
• Implementation of an ePRO Application for Health-Related Quality of Life (HrQoL) in Breast Cancer Patients: Evaluation and Usability Analysis (Preprint)

  2019cites this paper
• Targeted Breast Cancer Therapy

  2019cites this paper
• An Electronic Patient-Reported Outcome Tool for the FACT-B (Functional Assessment of Cancer Therapy-Breast) Questionnaire for Measuring the Health-Related Quality of Life in Patients With Breast Cancer: Reliability Study

  2019cites this paper
• Health-related quality of life in patients receiving first-line eribulin mesylate with or without trastuzumab for locally recurrent or metastatic breast cancer

  2019cites this paper
• This is a repository copy of Health-related quality of life in locally advanced and metastatic breast cancer: methodological and clinical issues in randomised controlled trials.

  2018cites this paper
• Metastatic and triple-negative breast cancer: challenges and treatment options

  2018cites this paper
• Combination therapies for the treatment of HER2-positive breast cancer: current and future prospects

  2018cites this paper
• Value assessment in oncology drugs: funding of drugs for metastatic breast cancer in Canada.

  2018cites this paper
• Short term real world safety data of pertuzumab use in HER2 targeted treatment of metastatic breast cancer

  2018cites this paper
• Real-World Data on Health-Related Quality of Life Assessment in Patients With Breast Cancer Receiving Subcutaneous Trastuzumab

  2018cites this paper
• Statistical analysis of patient-reported outcome data in randomised controlled trials of locally advanced and metastatic breast cancer: a systematic review.

  2018cites this paper
• A randomized, open-label, Phase III trial of pertuzumab retreatment in HER2-positive locally advanced/metastatic breast cancer patients previously treated with pertuzumab, trastuzumab and chemotherapy: the Japan Breast Cancer Research Group-M05 PRECIOUS study.

  2018cites this paper
• ESMO-Magnitude of Clinical Benefit Scale version 1.1

  2017cites this paper
• Gesundheitsbezogene Lebensqualität bei Brustkrebspatientinnen in der metastasierten oder adjuvanten Situation

  2017cites this paper
• Evolution of anti-HER2 therapies for cancer treatment.

  2017cites this paper
• Reliability of an e-PRO Tool of EORTC QLQ-C30 for Measurement of Health-Related Quality of Life in Patients With Breast Cancer: Prospective Randomized Trial

  2017cites this paper
• Development and clinical application of anti-HER2 monoclonal and bispecific antibodies for cancer treatment

  2017cites this paper
• Measuring the Value of New Drugs: Validity and Reliability of 4 Value Assessment Frameworks in the Oncology Setting.

  2017cites this paper
• Utilizing Solid Phase Cloning , Surface Display And Epitope Information for Antibody Generation and Characterization

  2017cites this paper
• Anti-Tumour Treatment Evolution of anti-HER 2 therapies for cancer treatment

  2017cites this paper
• Long-term health status as measured by EQ-5D among patients with metastatic breast cancer: comparison of first-line oral S-1 and taxane therapies in the randomized phase III SELECT BC trial

  2016cites this paper
• Health-related quality of life in locally advanced and metastatic breast cancer: methodological and clinical issues in randomised controlled trials.

  2016cites this paper
• Cost-Effectiveness of Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer.

  2016cites this paper
• Pertuzumab for the treatment of breast cancer: a safety review

  2016cites this paper
• Health-related Quality of Life in Metastatic and Adjuvant Breast Cancer Patients

  2016cites this paper
• Pertuzumab in HER2-positive breast cancer: a guide to its use

  2016cites this paper
• The use of patient-reported outcomes in advanced breast cancer clinical trials: a review of the published literature

  2016cites this paper
• Surrogate end points for overall survival in breast cancer trials: A review.

  2016cites this paper
• A standardised , generic , validated approach to stratify the magnitude of clinical bene fi t that can be anticipated from anti-cancer therapies : the European Society for Medical Oncology Magnitude of Clinical Bene fi t Scale ( ESMO-MCBS )

  2015cites this paper
• Efficacy and Safety of HER2-Targeted Agents for Breast Cancer with HER2-Overexpression: A Network Meta-Analysis

  2015cites this paper
• Современная парадигма лечения распространенного HER2-позитивного рака молочной железы: двойная блокада рецептора HER2 и конъюгаты моноклонального антитела с цитостатическим агентом

  2015cites this paper
• Health-related quality-of-life as co-primary endpoint in randomized clinical trials in oncology

  2015cites this paper
• Human epidermal growth factor receptor 2 positive (HER2+) metastatic breast cancer: how the latest results are improving therapeutic options

  2015cites this paper
• The expanding role of pertuzumab in the treatment of HER2-positive breast cancer

  2015cites this paper
• Sequential FOLFIRI.3 + Gemcitabine Improves Health-Related Quality of Life Deterioration-Free Survival of Patients with Metastatic Pancreatic Adenocarcinoma: A Randomized Phase II Trial

  2015cites this paper
• Targets Therapy The expanding role of pertuzumab in the treatment of HeR2-positive breast cancer

  2015cites this paper
• Pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer

  2015cites this paper
• Pertuzumab in HER2-positive breast cancer: a guide to its use

  2015influential citation
• A review of HER2-targeted therapy in breast and ovarian cancer: lessons from antiquity - CLEOPATRA and PENELOPE.

  2015cites this paper
• [Health-related quality of life in phase III cancer clinical trials: from questionnaire administration to statistical analysis].

  2015cites this paper
• The use of combinations of monoclonal antibodies in clinical oncology.

  2015cites this paper
• Pharmacokinetics, pharmacodynamics and clinical efficacy of pertuzumab in breast cancer therapy

  2015cites this paper
• A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS).

  2015cites this paper
• Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer.

  2015cites this paper
• Metastasiertes Mammakarzinom: Pertuzumab senkt die Lebensqualität nicht

  2014cites this paper
• Updates on the treatment of human epidermal growth factor receptor type 2-positive breast cancer

  2014cites this paper
• Pertuzumab for the Treatment of Breast Cancer

  2014cites this paper
• HER story: the next chapter in HER-2-directed therapy for advanced breast cancer.

  2013cites this paper
• Breast Cancer, Version 3.2013

  2013cites this paper
• Pertuzumab: A Review of Its Use for First-Line Combination Treatment of HER2-Positive Metastatic Breast Cancer

  2013influential citation
• HER2 Dimerization Inhibitor Pertuzumab - Mode of Action and Clinical Data in Breast Cancer

  2013cites this paper
• International Journal of Women's Health Dovepress Pertuzumab in Human Epidermal Growth-factor Receptor 2-positive Breast Cancer: Clinical and Economic Considerations

  year unknowncites this paper
• A modern paradigm for treating HER 2-positive advanced breast cancer : Dual HER 2 blockade and antibody-drug conjugates

  year unknowncites this paper